NG
NG9.F NeoGenomics Inc
- Market cap
- EUR 1.94B
- P/E
- -
- P/B
- 2.72x
- ROE
- -3.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NG9.F undervalued?
Graham numberThe Graham number of NeoGenomics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NeoGenomics Inc fundamental analysis
No fundamental analysis for NeoGenomics Inc yet.
NeoGenomics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detectin…
Full company profileNeoGenomics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NeoGenomics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 244M | 259M | 277M | 409M | 444M | 484M | 510M | 592M | 661M | 727M | 797M |
| Gross Profit | 110M | 120M | 127M | 197M | 186M | 187M | 188M | 245M | 290M | 314M | 359M |
| Operating Income | 6.04M | 3.38M | 10.0M | 13.0M | -14.0M | -119M | -153M | -96.6M | -85.4M | -88.1M | -47.9M |
| EBITDA | - | 24.7M | 31.8M | 37.6M | 28.7M | 43.4M | -88.4M | -17.6M | -1.51M | -38.7M | 36.9M |
| Net Income | -5.72M | -846K | 2.64M | 8.01M | 4.17M | -8.35M | -144M | -88.0M | -78.7M | -108M | -29.9M |
| EPS | - | -0.01 | 0.03 | 0.08 | 0.04 | -0.07 | -1.14 | -0.69 | -0.61 | -0.84 | -0.23 |
| Balance Sheet | |||||||||||
| Total Assets | 337M | 343M | 505M | 710M | 988M | 1.87B | 1.74B | 1.68B | 1.64B | 1.36B | 1.38B |
| Total Liabilities | 151M | 138M | 185M | 202M | 294M | 762M | 742M | 740M | 736M | 523M | 576M |
| Shareholders' Equity | 187M | 206M | 320M | 507M | 694M | 1.11B | 998M | 942M | 902M | 837M | 801M |
| Cash & Short-term Investments | 12.5M | 12.8M | 9.81M | 173M | 229M | 317M | 263M | 342M | 367M | 160M | 139M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 21.5M | 18.0M | 44.8M | 23.4M | 1.46M | -26.7M | -66.0M | -1.95M | 7.02M | 5.23M | 3.92M |
| Capital Expenditure | 7.54M | 13.7M | 14.3M | 20.0M | 29.1M | 64.1M | 30.9M | 28.8M | 41.1M | 27.0M | 33.3M |
| Free Cash Flow | - | 4.35M | 30.5M | 3.34M | -27.6M | -90.9M | -96.9M | -30.7M | -34.0M | -21.8M | -29.4M |
| Ratios | |||||||||||
| ROE | -3.1% | -0.4% | 0.8% | 1.6% | 0.6% | -0.8% | -14.5% | -9.3% | -8.7% | -12.9% | -3.7% |
| ROA | -1.7% | -0.2% | 0.5% | 1.1% | 0.4% | -0.4% | -8.3% | -5.2% | -4.8% | -7.9% | -2.2% |
| Net Profit Margin | -2.3% | -0.3% | 1.0% | 2.0% | 0.9% | -1.7% | -28.3% | -14.9% | -11.9% | -14.9% | -3.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NeoGenomics Inc dividends
NeoGenomics Inc has not paid dividends in the last 9 fiscal years.
Who owns NeoGenomics Inc
- Insiders 2.10%
- Institutions 97.90%
- Public & others 0.00%
- Shares outstanding 129M
- Free float 118M
NeoGenomics Inc company profile
- Company name
- NeoGenomics Inc
- Ticker
- NG9.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,500
- Fiscal year end
- December
- Address
- 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912
- Phone
- 239 768 0600
- Website
- neogenomics.com
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics Inc management
10- Mr. Anthony P. ZookCEO & Director · born 1961
- Mr. Warren StonePresident & COO · born 1973
- Ms. Elizabeth A. FloegelChief Digital & Information Officer · born 1976
- Mr. Gary PassmanChief People & Culture Officer
- Mr. Abhishek JainExecutive VP & CFO · born 1976
- Mr. Gregory D. AunanSenior VP & Chief Accounting Officer · born 1969
- Mr. Andrew Frederick Brackmann C.F.A.Vice President of Investor Relations
- Mr. Clarence Cooper Esq.Vice President of Compliance & Privacy
- Ms. Ellisa Cholapranee J.D.General Counsel
- Dr. Andrew A. Lukowiak Ph.D.Chief Innovation Officer · born 1972